Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy

Carlo Visco, Theodoros P. Vassilakopoulos, Kay Oliver Kliche, Gianpaolo Nadali, Simonetta Viviani, Valeria Bonfante, L. Jeffrey Medeiros, P. Notti, George Z. Rassidakis, Prema Peethambaram, Richard Wilder, Thomas Witzig, Massimo Gianni, Gianni Bonadonna, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando Cabanillas, Andreas H. Sarris

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.

Original languageEnglish
Pages (from-to)2085-2092
Number of pages8
JournalLeukemia and Lymphoma
Volume45
Issue number10
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Hodgkin Disease
Interleukin-10
Disease-Free Survival
Radiotherapy
Serum
Interleukin-2
Survivors
Histology
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
HIV
Lymphocytes
Biopsy

Keywords

  • Hodgkin's disease
  • Interleukin-10
  • Prognostic factors
  • Radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. / Visco, Carlo; Vassilakopoulos, Theodoros P.; Kliche, Kay Oliver; Nadali, Gianpaolo; Viviani, Simonetta; Bonfante, Valeria; Medeiros, L. Jeffrey; Notti, P.; Rassidakis, George Z.; Peethambaram, Prema; Wilder, Richard; Witzig, Thomas; Gianni, Massimo; Bonadonna, Gianni; Pizzolo, Giovanni; Pangalis, Gerassimos A.; Cabanillas, Fernando; Sarris, Andreas H.

In: Leukemia and Lymphoma, Vol. 45, No. 10, 10.2004, p. 2085-2092.

Research output: Contribution to journalArticle

Visco, C, Vassilakopoulos, TP, Kliche, KO, Nadali, G, Viviani, S, Bonfante, V, Medeiros, LJ, Notti, P, Rassidakis, GZ, Peethambaram, P, Wilder, R, Witzig, T, Gianni, M, Bonadonna, G, Pizzolo, G, Pangalis, GA, Cabanillas, F & Sarris, AH 2004, 'Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy', Leukemia and Lymphoma, vol. 45, no. 10, pp. 2085-2092. https://doi.org/10.1080/10428190410001712234
Visco, Carlo ; Vassilakopoulos, Theodoros P. ; Kliche, Kay Oliver ; Nadali, Gianpaolo ; Viviani, Simonetta ; Bonfante, Valeria ; Medeiros, L. Jeffrey ; Notti, P. ; Rassidakis, George Z. ; Peethambaram, Prema ; Wilder, Richard ; Witzig, Thomas ; Gianni, Massimo ; Bonadonna, Gianni ; Pizzolo, Giovanni ; Pangalis, Gerassimos A. ; Cabanillas, Fernando ; Sarris, Andreas H. / Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 10. pp. 2085-2092.
@article{d52ea03fa6de48c88cdb65ed8f1c724c,
title = "Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy",
abstract = "Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52{\%} were males, and 3{\%} had B-symptoms. Ann Arbor Stage was I in 35{\%}, II in 58{\%}, and III in 7{\%} of the patients. Histology was lymphocyte predominance in 26{\%}, and classical HD in 74{\%} of the patients. Serum IL-10 was elevated in 35{\%} of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50{\%} vs. 81{\%} (all patients, P = 0.006), and 43{\%} vs. 77{\%} for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57{\%}, 36{\%}, and 7{\%} of the population, and their 5-year PFS was 80{\%}, 63{\%}, and 0{\%}, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.",
keywords = "Hodgkin's disease, Interleukin-10, Prognostic factors, Radiotherapy",
author = "Carlo Visco and Vassilakopoulos, {Theodoros P.} and Kliche, {Kay Oliver} and Gianpaolo Nadali and Simonetta Viviani and Valeria Bonfante and Medeiros, {L. Jeffrey} and P. Notti and Rassidakis, {George Z.} and Prema Peethambaram and Richard Wilder and Thomas Witzig and Massimo Gianni and Gianni Bonadonna and Giovanni Pizzolo and Pangalis, {Gerassimos A.} and Fernando Cabanillas and Sarris, {Andreas H.}",
year = "2004",
month = "10",
doi = "10.1080/10428190410001712234",
language = "English",
volume = "45",
pages = "2085--2092",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy

AU - Visco, Carlo

AU - Vassilakopoulos, Theodoros P.

AU - Kliche, Kay Oliver

AU - Nadali, Gianpaolo

AU - Viviani, Simonetta

AU - Bonfante, Valeria

AU - Medeiros, L. Jeffrey

AU - Notti, P.

AU - Rassidakis, George Z.

AU - Peethambaram, Prema

AU - Wilder, Richard

AU - Witzig, Thomas

AU - Gianni, Massimo

AU - Bonadonna, Gianni

AU - Pizzolo, Giovanni

AU - Pangalis, Gerassimos A.

AU - Cabanillas, Fernando

AU - Sarris, Andreas H.

PY - 2004/10

Y1 - 2004/10

N2 - Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.

AB - Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P <0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.

KW - Hodgkin's disease

KW - Interleukin-10

KW - Prognostic factors

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=4544339987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544339987&partnerID=8YFLogxK

U2 - 10.1080/10428190410001712234

DO - 10.1080/10428190410001712234

M3 - Article

C2 - 15370254

AN - SCOPUS:4544339987

VL - 45

SP - 2085

EP - 2092

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -